Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
| ▸ | CES1 | P23141 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL652387 | 1.00 | ALDH1A1 (0.33) | ALDH1A1HSD17B10CYP1A2CES2CES1 | |
| SCHEMBL11889302 | 1.00 | ALDH1A1 (0.33) | ALDH1A1HSD17B10CYP1A2CES2CES1 | |
| SCHEMBL2004894 | 0.96 | ALDH1A1 (0.36) | ALDH1A1 | |
| Biphenyl SCHEMBL25345143 | 0.89 | ALDH1A1 (0.53) | ALDH1A1 | |
| SCHEMBL15915221 | 0.72 | ALDH1A1 (0.32) | ALDH1A1HSD17B10 | |
| Lithium Ion SCHEMBL3805405 | 0.70 | EPHX1 (0.30) | — | |
| SCHEMBL7741586 | 0.69 | EPHX1 (0.48) | ALDH1A1HSD17B10CYP1A2 | |
| SCHEMBL20815401 | 0.69 | ALDH1A1 (0.30) | ALDH1A1HSD17B10 | |
| SCHEMBL22068846 | 0.69 | NOS3 (0.32) | ALDH1A1HSD17B10 | |
| SCHEMBL1287904 | 0.69 | KEAP1 (0.33) | ALDH1A1HSD17B10CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368604-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-12-04 | — | — | US | claimed |
| CN-118373875-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2024-07-23 | — | — | CN | claimed |
| US-4453028-A | BLOOD SUBSTITUTES | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, THE | 1984-06-05 | — | — | US | claimed |
| US-20250376443-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250368604-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-12-04 | — | — | US | disclosed |
| US-12351648-B2 | Methods of inhibiting MASP-2 for the treatment and/or prevention of coronavirus-induced acute respiratory distress syndrome | OMEROS CORPORATION (US) | 2025-07-08 | — | — | US | disclosed |
| US-20250129020-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-04-24 | — | — | US | disclosed |
| CN-119350433-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2025-01-24 | — | — | CN | disclosed |
| US-12195427-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2025-01-14 | — | — | US | disclosed |
| EP-4484448-A2 | METHODS OF INHIBITING MASP-2 FOR THE TREATMENT AND/OR PREVENTION OF CORONAVIRUS-INDUCED ACUTE RESPIRATORY DISTRESS SYNDROME | Omeros Corporation (US) | 2025-01-01 | — | — | EP | disclosed |
| EP-4484447-A2 | METHODS OF INHIBITING MASP-2 FOR THE TREATMENT AND/OR PREVENTION OF CORONAVIRUS-INDUCED ACUTE RESPIRATORY DISTRESS SYNDROME | Omeros Corporation (US) | 2025-01-01 | — | — | EP | disclosed |
| CN-117964684-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-117964683-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2024-05-03 | — | — | CN | disclosed |
| EP-4288098-A1 | BIOMARKER FOR ASSESSING THE RISK OF DEVELOPING ACUTE COVID-19 AND POST-ACUTE COVID-19 | Omeros Corporation (US) | 2023-12-13 | — | — | EP | disclosed |
| CN-116646533-A | Catalyst for dehydrogenation reaction, method for producing same, and hydrogen production method using same | 现代自动车株式会社 | 2023-08-25 | — | — | CN | disclosed |
| US-11584714-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-02-21 | — | — | US | disclosed |
| EP-4114522-A1 | METHODS OF INHIBITING MASP-2 FOR THE TREATMENT AND/OR PREVENTION OF CORONAVIRUS-INDUCED ACUTE RESPIRATORY DISTRESS SYNDROME | Omeros Corporation (US) | 2023-01-11 | — | — | EP | disclosed |
| CN-115335120-A | Method for inhibiting MASP-2 for the treatment and/or prevention of coronavirus induced acute respiratory distress syndrome | 奥默罗斯公司 | 2022-11-11 | — | — | CN | disclosed |
| US-20220308056-A1 | BIOMARKER FOR ASSESSING THE RISK OF DEVELOPING ACUTE COVID-19 AND POST-ACUTE COVID-19 | OMEROS CORPORATION | 2022-09-29 | — | — | US | disclosed |
| WO-2022170090-A1 | BIOMARKER FOR ASSESSING THE RISK OF DEVELOPING ACUTE COVID-19 AND POST-ACUTE COVID-19 | OMEROS CORPORATION (US) | 2022-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584714-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | ALDH1A1 4701/4885HSD17B10 3043/4885CYP1A2 4233/4885 |
| US-12351648-B2 | Methods of inhibiting MASP-2 for the treatment and/or prevention of coronavirus-induced acute respiratory distress syndrome | MASP2, ACE2, MAS1 | ALDH1A1 4482/4885HSD17B10 4491/4885CYP1A2 1828/4885 |
| US-20250368604-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | ALDH1A1 4701/4885HSD17B10 3043/4885CYP1A2 4233/4885 |
| US-12195427-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | ALDH1A1 4701/4885HSD17B10 3043/4885CYP1A2 4233/4885 |
| US-20250376443-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | ALDH1A1 4718/4885HSD17B10 3299/4885CYP1A2 4289/4885 |
| US-20250129020-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | ALDH1A1 4701/4885HSD17B10 3043/4885CYP1A2 4233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.